CASC
Cascadian Therapeutics, Inc.
CASC
CASC
Delisted
CASC was delisted on the 8th of March, 2018.
91 hedge funds and large institutions have $152M invested in Cascadian Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
91
Holders Change
+12
Holders Change %
+15.19%
% of All Funds
2.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
30
Reduced
19
Closed
5
Calls
$50K
Puts
$1K
Net Calls
+$49K
Net Calls Change
-$21K
Top Buyers
| 1 |
1
BlackRock
New York
|
$10.1M |
| 2 |
ACA
2
Avoro Capital Advisors
New York
|
$9.2M |
| 3 |
PC
3
Polar Capital
London,
United Kingdom
|
$7.03M |
| 4 |
4
Goldman Sachs
New York
|
$2.46M |
| 5 |
KCM
5
Kennedy Capital Management
St Louis,
Missouri
|
$1.83M |
